In the day's ablation trial, the sham group's quality-of-life score rose 15.7 points. Those patients had a groin puncture, a catheter, sedation and a period of being looked after intensively by people who believed they were being treated - and no ablation. Whatever produced that 15.7 points is present in every unblinded procedural trial ever run, sitting inside the single-arm improvement that gets quoted to patients.
The practical habit: when you cite a symptom benefit from an unblinded procedural study, say what it was compared against. If the comparison was baseline, the number includes regression to the mean, natural fluctuation of a relapsing condition, and the effect of the ritual itself. That is not a reason to withhold the procedure. It is a reason not to attribute all of the improvement to the part that carries the risk.
- Ask what the comparator was before quoting a symptom improvement figure to a patient.
- Treat before-and-after improvement in a relapsing condition as an upper bound, not an estimate.
- Separate the parts of a procedure that carry risk from the parts that carry reassurance when consenting.
- Where a sham-controlled trial exists for a procedure, use its between-group difference, not its treatment-arm change.
- Expect large placebo responses specifically in symptom and quality-of-life endpoints, less so in mortality.
Why it matters
The number most often quoted at consent for a symptom-relieving procedure is the one that includes everything except the procedure's specific effect.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for top clinical updates, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free